HSD17B13 / 17-beta-hydroxysteroid dehydrogenase 13 · IHC design guide

Design Immunohistochemistry for HSD17B13

Plan paraffin-section HSD17B13 IHC with the IHC-validated antibody at 2–5 μg/ml (datasheet A12700-1). Assess cytoplasmic Leydig-cell staining and low hepatocyte staining, while accounting for the tissue IHC profile’s uncertain reliability (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for HSD17B13 (IHC for HSD17B13): expected localisation Cytoplasmic staining (HPA tissue IHC); ER and lipid droplets expected (UniProt), antibody A12700-1, validated IHC image, and IHC protocol steps — Printable **HSD17B13** IHC protocol sheet — expected localisation Cytoplasmic staining (HPA tissue IHC); ER and lipid droplets expected (UniProt), antibody A12700-1, controls and protocol steps. Open the full HSD17B13 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

HSD17B13 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining (HPA tissue IHC); ER and lipid droplets expected (UniProt)
	Staining pattern	Cytoplasmic Leydig cells; marrow subsets and plasma positive (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet A12700-1)
	Positive control ⓘ	Testis
	Negative control ⓘ	Adrenal gland+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific)
	Caveat	Tissue staining awaits external verification (HPA tissue IHC)
	Regulation	Liver-enriched RNA (HPA tissue RNA)
	Isoform / epitope	2 isoforms; no TM segment; check epitope coverage (UniProt)

Section 1

Recommended HSD17B13 IHC & IF Protocols

The catalog antibody protocol uses EDTA pH 8.0 heat retrieval (datasheet A12700-1). The published human organoid IHC protocol specifies DAB detection (PMC13475973).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet A12700-1)
Fixation	Image fixative and duration unreported (datasheet A12700-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet A12700-1); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A12700-1)
Primary antibody	Rabbit anti-HSD17B13, 2-5 μg/ml (datasheet A12700-1)
Primary incubation	Overnight at 4 °C (datasheet A12700-1)
Detection	HRP-conjugated secondary, DAB chromogen (datasheet A12700-1)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	HSD17B13-positive staining in leydig cells of testis (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in Leydig cells, subsets of cells in bone marrow and positivity in plasma. No signal in the no-primary control.

💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A12700-1); the organoid article does not report a retrieval condition (PMC13475973).

Section 2

What Is the Expected HSD17B13 Staining Pattern?

HSD17B13 localizes to the cytoplasm, endoplasmic reticulum and lipid droplets, and has no transmembrane segment (UniProt Q7Z5P4). In tissue IHC, expect cytoplasmic staining in Leydig cells and some bone marrow cells; hepatocyte staining is reported at low levels (HPA tissue IHC). Interpret these patterns cautiously: the HPA tissue IHC profile is rated Uncertain, pending external verification (HPA tissue IHC).

What am I looking at on my slide?
Cytoplasmic staining in Leydig cells, with some staining in bone marrow cells (HPA tissue IHC).	This fits the reported tissue pattern. Leydig cell staining is Medium; the bone marrow finding applies to subsets of cells, not every cell (HPA tissue IHC). Compare the stained cells with tissue morphology before scoring (general IHC practice).
Staining confined to nuclei or outlining cell surfaces, with little cytoplasmic signal.	That distribution does not match the reported cytoplasmic tissue pattern or the annotated cytoplasm, endoplasmic reticulum and lipid droplet locations (HPA tissue IHC; UniProt Q7Z5P4). Treat it as suspect and check controls before assigning a specific compartment (general IHC practice).
Strong staining in cells where the supplied HPA tissue profile reports no detection.	The result conflicts with that cell type's HPA observation, but the profile is rated Uncertain (HPA tissue IHC). Check morphology, a no-primary control and detection background; cross-reactivity or endogenous detection activity may explain the signal (general IHC practice).
Diffuse color across the section, including spaces outside cells.	Diffuse deposition does not establish cellular HSD17B13 localization (general IHC practice). HPA also reports plasma positivity, so distinguish apparent extracellular signal from a defined cytoplasmic cell pattern (HPA tissue IHC). Review the no-primary control and washing (general IHC practice).
No visible staining in Leydig cells on an otherwise interpretable section.	Leydig cells are a reported Medium-staining population, although the tissue profile remains Uncertain (HPA tissue IHC). First verify tissue identity and section quality, then review antibody incubation, detection and controls before concluding that HSD17B13 is absent (general IHC practice).

💡Expected HSD17B13 appearanceCall a result consistent when staining is chiefly cytoplasmic in Leydig cells at Medium intensity, allowing weaker hepatocyte staining; isolated nuclear, surface-only or diffuse extracellular color is suspect (HPA tissue IHC; UniProt Q7Z5P4).

How each factor affects the staining
Tissue and cell choice	HPA reports Medium staining in testis Leydig cells and Low staining in liver hepatocytes, while UniProt describes liver as highly expressed (HPA tissue IHC; UniProt Q7Z5P4). Use the observed IHC levels when judging slide intensity; expression and staining reports need not give identical intensity rankings.
Antibody validation	HPA029125 is rated Uncertain for IHC and Approved for ICC (HPA antibodies). An ICC rating does not validate a paraffin-section result. Require appropriate tissue morphology and controls before treating a new IHC pattern as specific (general IHC practice).
Subcellular resolution	UniProt places HSD17B13 at lipid droplets and the endoplasmic reticulum and notes redistribution toward lipid droplets when droplet formation is induced (UniProt Q7Z5P4). Chromogenic IHC can support a cytoplasmic call, but does not by itself identify the organelle carrying the stain (general IHC practice).
Processing and isoforms	UniProt lists a signal sequence at residues 1–19, a chain at 20–300 and 2 isoforms (UniProt Q7Z5P4). The payload gives no antibody epitope, so it cannot establish which forms the IHC antibody recognizes or predict a staining difference between them.
IF/ICC Q: Should its localization define the paraffin IHC pattern?	A: HPA reports vesicles as the main ICC-IF location and the Golgi apparatus as an additional location, with ICC rated Approved for HPA029125 (HPA subcellular; HPA antibodies). Use that as context, while judging paraffin IHC against its tissue pattern and Uncertain IHC rating (HPA tissue IHC; HPA antibodies).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Leydig cells show no signal.	The observed result falls below the reported Medium level, though HPA rates this tissue profile Uncertain (HPA tissue IHC). A failed staining run or weak detection is also possible (general IHC practice).	Confirm testis morphology, inspect the run's controls, and review the IHC-validated antibody incubation and chromogenic detection steps before interpreting the absence (general IHC practice).
Hepatocytes stain weakly while Leydig cells stain more clearly.	That intensity order matches HPA's Low hepatocyte and Medium Leydig cell observations, despite UniProt's description of high liver expression (HPA tissue IHC; UniProt Q7Z5P4).	Score each tissue by its observed cell pattern and HPA IHC level. Do not require liver staining to exceed Leydig cell staining solely because liver expression is described as high.
Color appears in HPA-listed cells with no detected staining.	Possible cross-reactivity, endogenous detection activity or misidentified cells; the HPA profile itself remains Uncertain (HPA tissue IHC; general IHC practice).	Recheck morphology and a no-primary control. If using an enzyme-based detector, assess its endogenous-activity control before attributing the color to HSD17B13 (general IHC practice).
Most nuclei stain, but cytoplasm does not.	A nuclear-dominant pattern conflicts with the reported cytoplasmic tissue staining and annotated cellular locations (HPA tissue IHC; UniProt Q7Z5P4).	Compare with the counterstain and no-primary control, and review detection and washing. Withhold a positive HSD17B13 call until a credible cytoplasmic pattern is present (general IHC practice).
The section has widespread diffuse chromogen.	General detection background can obscure cell boundaries (general IHC practice). HPA's report of plasma positivity also makes extracellular-looking color an interpretation issue (HPA tissue IHC).	Inspect the no-primary control and tissue morphology; review blocking, washing and chromogen development as general IHC workflow checks. Score defined cells only when their cytoplasm can be distinguished (general IHC practice).
A punctate IF/ICC image seems inconsistent with diffuse-looking chromogenic IHC.	HPA describes vesicles and Golgi localization in ICC-IF, whereas its tissue IHC summary describes cytoplasmic expression (HPA subcellular; HPA tissue IHC). The two observations have different spatial detail.	Interpret the paraffin slide at the cell and cytoplasmic level. Reserve an organelle-specific assignment for imaging that can resolve and verify that compartment (general IHC/IF practice).

Source: UniProt Q7Z5P4 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing HSD17B13 staining

IHC analysis of HSD17B13 using anti-HSD17B13 antibody (A12700-1). HSD17B13 was detected in a paraffin-embedded section of human liver cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-HSD17B13 Antibody (A12700-1) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

A12700-1 · IHCIHC analysis of HSD17B13 using anti-HSD17B13 antibody (A12700-1). HSD17B13 was detected in a paraffin-embedded section of human liver cancer

IHC analysis of HSD17B13 using anti-HSD17B13 antibody (A12700-1). HSD17B13 was detected in a paraffin-embedded section of human pancreas ductal adenocarcinoma tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-HSD17B13 Antibody (A12700-1) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

A12700-1 · IHCIHC analysis of HSD17B13 using anti-HSD17B13 antibody (A12700-1). HSD17B13 was detected in a paraffin-embedded section of human pancreas duc

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000170509-HSD17B13/tissue/cerebral+cortex#imid_8371612

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000170509-HSD17B13/tissue/colon#imid_8371538

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000170509-HSD17B13/tissue/liver#imid_8371523

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000170509-HSD17B13/tissue/kidney#imid_8371532

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029125; green = HSD17B13, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for HSD17B13 IHC & IF

🧪Run testis first and look for staining in Leydig cells (Medium; HPA: testis, Leydig cells). Run adrenal gland glandular cells as the negative tissue (HPA: Not detected); on the testis slide, surrounding non-Leydig cells should provide a background reference rather than be assumed entirely negative (HPA: Leydig-cell staining reported).

Positive control tissue: Testis (Leydig cells, HPA Medium)

Negative control tissue: Adrenal gland (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HSD17B13 in A-431, U-251MG, U2OS, with annotated localisation: Vesicles (approved) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control; a rabbit IgG isotype control matched to the primary antibody’s clonality where known (caption: rabbit anti-HSD17B13); and HSD17B13-knockout tissue or a validated peptide-block control (standard IHC practice). Quench endogenous peroxidase and inspect unstained testis tissue for pigment that could be mistaken for DAB signal (standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A12700-1 paraffin-section caption does not state the fixative (caption: fixative not stated). The caption uses heat retrieval in EDTA, pH 8.0, providing a starting condition without establishing that retrieval is required (caption: heat-mediated EDTA retrieval). The supplied evidence does not show that frozen sections or IF/ICC are easier; testis pigment should be checked against the negative controls when scoring chromogenic staining (standard IHC practice).

HPA tissue IHC evidence for HSD17B13

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Testis	Leydig cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →
Cerebellum	Cells in granular layer	Not detected	Protein (IHC)	HPA →

Section 3

Advanced HSD17B13 IHC Tips

Troubleshooting HSD17B13 staining in paraffin sections requires attention to retrieval, compartmental pattern, cell identity, and controls for chromogenic detection.

How should I retrieve HSD17B13 in paraffin sections when staining is weak?

Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A12700-1). That condition was used for the catalog antibody in a paraffin-embedded human liver cancer section, followed by 2 μg/ml primary antibody overnight at 4°C (datasheet A12700-1). If staining remains weak, compare retrieval duration on serial sections while holding antibody concentration and detection constant; excessive heating can impair tissue morphology (standard IHC practice). Include a no-primary control and assess both staining and section integrity before changing buffer chemistry (standard IHC practice). A different buffer or pH would be an optimization experiment, not a documented condition for this antibody (datasheet A12700-1).

Could fixation explain inconsistent HSD17B13 staining between tissue blocks?

Target-specific fixation sensitivity is unknown: the paraffin-section caption does not state a fixative (datasheet A12700-1). Record each block’s fixative, fixation duration, section thickness, and storage history before comparing staining intensity, because these variables can change antigen accessibility in IHC (standard IHC practice). Process serial sections with the documented EDTA retrieval at pH 8.0 and keep the primary incubation at 2 μg/ml overnight at 4°C while investigating block effects (datasheet A12700-1). Compare morphology and signal against a concurrently processed reference section, and treat any apparent fixation effect as an experimental observation rather than an established HSD17B13 property (standard IHC practice).

What staining pattern should I expect for HSD17B13 in IHC?

Evaluate HSD17B13 primarily as a cytoplasmic signal, with attention to punctate or organelle-associated staining rather than assuming uniform cytosolic labeling (UniProt Q7Z5P4 subcellular location). UniProt places the protein at lipid droplets and endoplasmic reticulum and reports redistribution toward lipid droplets when droplet formation is induced (UniProt Q7Z5P4 subcellular location). HPA reports mainly vesicular localization with additional Golgi localization in cell imaging, which provides context but does not define the appearance of chromogenic tissue staining (HPA subcellular). Review stained cells at higher magnification alongside a counterstain, and compare the pattern with a no-primary control before calling diffuse deposits specific (standard IHC practice).

How can isoforms or epitope accessibility complicate HSD17B13 IHC?

HSD17B13 has 2 listed isoforms, so antibody recognition across isoforms cannot be assumed without an epitope map or direct validation (UniProt Q7Z5P4 isoforms). The record describes a 300-amino-acid precursor, a signal sequence at residues 1–19, and a processed chain at residues 20–300; an epitope’s position could therefore matter for interpretation (UniProt Q7Z5P4 processing). No epitope location is supplied for A12700-1, so a negative section cannot establish that an isoform is absent (datasheet A12700-1; UniProt Q7Z5P4 isoforms). Compare serial sections under matched retrieval and detection conditions, then seek independent antibody or transcript evidence if an isoform-specific conclusion is essential (standard IHC practice).

How should I follow up an IHC pattern with multiplex immunofluorescence?

Treat IF as a separate assay requiring its own antibody and fixation validation; the supplied A12700-1 example documents chromogenic staining of a paraffin section (datasheet A12700-1). Pair HSD17B13 with a validated marker for the cell population being evaluated, such as a hepatocyte marker in liver, and inspect both single channels before interpreting overlap (UniProt Q7Z5P4 tissue specificity; standard IF practice). Choose fluorophores and imaging settings after checking tissue autofluorescence with an unstained control, and avoid calling coincident background true colocalization (standard IF practice). Because HSD17B13 lacks an annotated transmembrane segment, select and test permeabilization for the antibody’s mapped epitope and the compartments being examined; its epitope side is not supplied here (UniProt Q7Z5P4 topology; standard IF practice).

What controls help distinguish HSD17B13 staining from chromogenic background?

Run a no-primary control through secondary detection and DAB development to reveal nonspecific detector signal and endogenous peroxidase activity (standard IHC practice). Include a peroxidase-blocking step, then compare reagent-only deposits with staining in intact, counterstained cells; these are general chromogenic IHC safeguards (standard IHC practice). The catalog example used 10% goat serum, a peroxidase-conjugated anti-rabbit secondary for 30 minutes at 37°C, and DAB detection (datasheet A12700-1). If background persists, optimize blocking and washing while holding retrieval at EDTA pH 8.0, and judge changes against tissue morphology and the no-primary control (datasheet A12700-1; standard IHC practice).

How should I quantify HSD17B13 across paraffin tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment to be scored before reviewing treatment groups, then apply the same threshold and imaging settings across sections (standard IHC practice). For cellular staining, report the percentage of positive cells and an H-score using intensity grades 0–3; for discrete positive cells, density per mm² can also be useful (standard IHC practice). Normalize counts to the number of eligible, intact cells or measured viable tissue area, and record exclusions for necrosis and tissue loss (standard IHC practice). Because liver RNA is enriched while HPA reports low hepatocyte protein staining and uncertain tissue-IHC reliability, avoid using either source as a fixed intensity calibration (HPA tissue IHC).

When should I question a positive HSD17B13 IHC result?

Question staining confined to section edges, necrotic areas, or no-primary controls, since these patterns can reflect processing or detection artifacts (standard IHC practice). Check whether signal is associated with cytoplasm and plausible organelle-rich regions: HSD17B13 is reported at lipid droplets, endoplasmic reticulum, and cytoplasm, without an annotated transmembrane segment (UniProt Q7Z5P4 subcellular location and topology). Check cell identity as well; UniProt reports high liver expression, whereas HPA describes low hepatocyte staining and medium Leydig-cell staining with uncertain tissue-IHC reliability (UniProt Q7Z5P4 tissue specificity; HPA tissue IHC). Investigate isolated nuclear deposits or broadly uniform DAB signal with no-primary and peroxidase-block controls before assigning them to HSD17B13 (standard IHC practice).

Boster reagents

Best HSD17B13 / 17-beta-hydroxysteroid dehydrogenase 13 IHC Antibodies

A12700-1 has IHC images from paraffin sections of human liver cancer, pancreatic ductal adenocarcinoma, and testicular seminoma (catalog IHC captions); no IF data are supplied (catalog IF fields).

Real IHC data

Anti-HSD17B13 Antibody ®

Cat # A12700-1

View product →

A12700-1 is listed for IHC and reacts with human, mouse, and rat (catalog applications; catalog reactivity). Its IHC captions document staining in paraffin sections of human liver cancer, pancreatic ductal adenocarcinoma, and testicular seminoma (catalog IHC captions).

Which to pick: Choose A12700-1 for paraffin-section tissue IHC: its captions report EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody, but do not report the fixative (catalog IHC captions). For IF/ICC, this catalog supplies no IF application, image, or dilution for A12700-1 (catalog applications; catalog IF fields). A12700-1 lists mouse and rat reactivity, while its supplied IHC images document human samples only; establish IHC performance in other species before interpreting staining (catalog reactivity; catalog IHC captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q7Z5P4 (DHB13_HUMAN, 17-beta-hydroxysteroid dehydrogenase 13).
Human Protein Atlas. HSD17B13 tissue IHC expression (reliability: Uncertain).
Human Protein Atlas. HSD17B13 subcellular location (ICC-IF): Mainly localized to vesicles. In addition localized to the Golgi apparatus..
Human Protein Atlas. HSD17B13 antibody validation summary (1 antibodies).
IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Science advances 2023 — PMC10104468.
The Hsd17b13(P260S) patient variant knock-in male mouse model provides translational insights into HSD17B13 biology. EBioMedicine 2026 — PMC13499355.
HSD17B13: A Potential Therapeutic Target for NAFLD. Frontiers in molecular biosciences 2021 — PMC8776652.
A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing. PloS one 2026 — PMC13475973.
PubMed PMID:17311113 — UniProt-cited evidence.
PubMed PMID:12975309 — UniProt-cited evidence.
PubMed PMID:15221005 — UniProt-cited evidence.